ORIGINAL PAPER



Organocatalytic one-pot synthesis of functionalized 1,3-oxathiolanes and 1,3-thiazolidines

Majid Ghazanfarpour-Darjani¹ · Alieh Khodakarami¹

Received: 18 May 2015/Accepted: 21 July 2015 © Springer-Verlag Wien 2015

Abstract An efficient organocatalytic approach for the synthesis of 1,3-oxathiolanes and 1,3-thiazolidines is reported. In this methodology, conjugated base of nitromethane was employed as a potential organocatalyst to promote cyclization reaction between strained heterocyclic compounds and heterocumulenes at ambient conditions. *Graphical abstract*

Keywords Heterocycles · One-pot reaction · Strained heterocycle · Organocatalytic · Heterocumulene

Introduction

Three-membered heterocyclic rings are valuable building block due to their ability to function as carbon electrophiles [1, 2]. These substrates undergo nucleophilic attack with heterocumulenes either at C-2 or C-3 position to afford corresponding heterocyclic compounds [3–6]. The extent of regioselectivity depends mainly on operating conditions

Published online: 05 August 2015

and ring substituents [7, 8]. Furthermore, most of these nucleophilic ring opening (NRO) transformations rely on catalysts such as metal catalysts [9, 10] or organocatalysts to accomplish the desired transformation [11]. The advantages of organocatalysts include their lack of sensitivity to moisture and oxygen, low cost, and low toxicity, although their catalytic efficiency is usually lower than in metal-catalyzed processes in terms of turnover number. 1,3-Oxathiolane and 1,3-thiazolidine derivatives are found in a wide range of bioactive compounds [12, 13]. In recent years, several different methods for the synthesis of these heterocycles have been reported [14-17]. Hou has also disclosed a concise procedure for the construction of 1,3thiazolidines using organophosphines [18]. These results encouraged us to examine alternative conditions for the synthesis of 1,3-thiazolidines and 1,3-oxathiolanes in the presence of Et₃N in nitromethane (MeNO₂).

Results and discussion

The reaction was initially examined using CS₂ (1) and 2-methyloxirane (2a) in the presence of pyridine as a base. Stirring in MeNO₂ at ambient conditions for 6 h gave 5-methyl-1,3-oxathiolane-2-thione (3a) in 69 % yield. To develop the reaction conditions a variety of bases and solvents were examined (Table 1). No reaction took place in the absence of a base even at higher temperatures. Among the bases examined, Et₃N gave the best result. The yield was almost unchanged by the reducing amount of Et₃N to 10 mol % (Table 1). Other solvents, such as THF, MeCN, DMF, hexane, and H₂O were also examined; however, no transformation occurred in the absence of MeNO₂ (Table 1). It could be deduced that MeNO₂ involves in reaction progress beyond acting as the solvent.



Majid Ghazanfarpour-Darjani m.ghazanfarpour@modares.ac.ir

Young Researchers and Elite Club, Islamic Azad University, Buin Zahra Branch, Qazvin, Iran

Table 1 Optimization of reaction conditions

Entry	Base	Solvent	3a ^a Yield/%
1	Et ₃ N	MeNO ₂	94
2	Et_3N	$MeNO_2$	96 ^b
3	Et ₃ N	$EtNO_2$	79
4	Et ₃ N	DMF	-
5	Pyridine	$MeNO_2$	69
6	DMAP	$MeNO_2$	10
7	DBU	$MeNO_2$	72
8	DABCO	$MeNO_2$	43

^a Reaction conditions: 1 (3 mmol), 2a (1.0 mmol), base (10 mol %), solvent (2 cm³), 25 °C for 6 h

Finally, optimal results for this transformation were obtained when 10 mol % of Et_3N in $MeNO_2$ (2 cm³) was used, furnishing **3a** in 94 % yield. The *trans*-structure of product was determined by the coupling constant of the two bridgehead hydrogens (**3a**, J = 11.4 Hz).

We next sought to explore the scope of the reaction (Table 2) using a wide range of oxiranes. Ring opening of alkyl-substituted oxiranes proceeded with good yields (Table 2). However, no reaction took place in the presence of cyclopentene and cyclooctene oxide as the oxirane sources due to the high strain energy of the product. Oxirane derived from cyclohexene gave excellent yield while cyclopentene oxide only afforded the product in moderate yield (Table 2). In the presence of alkyl-substituted oxiranes, the attack occurred exclusively at the terminal position, though styrene oxide gave benzylic-attacked product in high yield (Table 2). Isothiocyanates 4 were also examined and exhibited similar reactivity pattern to that observed with CS₂. In all cases, the corresponding 1,3oxathiolane-2-imine was obtained in good yield together with 3-8 % of hydrolyzed isothiocyanate. These products could be easily removed due to their different solubility from 5 (Table 2).

The reaction condition described above could also be extended to those with aziridines 6 (Table 3), providing corresponding heterocycles 7 or 8 in acceptable yields. However, aziridines 6 required longer reaction times to accomplish the transformation.

The structures of the products were confirmed by spectroscopic analyses. For example, the ¹H NMR spectrum of **3a** showed characteristic (AB)X spin system for the CH₂-CH H-atoms, together with a doublet for the methyl group. The ¹³C NMR spectrum of **3a** exhibited 4 signals in agreement with the proposed structure. The characteristic signal at 227 ppm belongs to the C-S double bond.

Although the mechanistic details of the formation of the products are not known, a plausible rationalization is proposed in Scheme 1. It is conceivable that the reaction starts with the formation of intermediate 11, followed by addition of oxirane to generate ring-opened intermediate 12. Cyclization of this adduct leads to formation of the intermediate 13, which is converted to 3a by elimination of the conjugated base of MeNO₂. However, another possibility could involve the attack of 10 to heterocumulenes.

In conclusion, we have described an organocatalytic approach for the synthesis of functionalized 1,3-oxathiolanes and 1,3-thiazolidines. The reaction was completely regio-selective and in all cases only one regio-isomer was detected in NMR analyses. Electronic and steric variations of the substrates showed no appreciable change in the efficiency of the transformation. Several functional groups such as methyl methacrylate, alkoxy, phenoxy, allyl, and halide could be well tolerated. Using this procedure, a simple etheric extraction would suffice to isolate the pure product.



b 1.0 mmol of Et₃N was used

Table 2 Synthesis of functionalized 1,3-oxathiolanes

4	R ¹	2	R^2 , R^3 , R^4	3ª yield/%	5 ^b yield/%
4a	Ph	2a	Me, H	3a , 95	5a , 91
4a	Ph	2 b	Et, H, H	3b , 93	5b , 90
4a	Ph	2 c	Ph, H, H	3c , 94 ^c	5c , 92 ^c
4a	Ph	2d	(CH ₃) ₂ CHOCH ₂ , H, H	3d , 94	5d , 90
4a	Ph	2e	Ph, Ph, H (cis)	3e , 96	5e , 94
4a	Ph	2f	PhOCH ₂ , H	3f , 94	5f , 91
4a	Ph	2 g	CH ₂ CCH ₃ COOCH ₂ , H, H	3g , 97	5g , 95
4a	Ph	2h	CH ₂ CHCH ₂ OCH ₂ , H, H	3h , 90	5h , 87
4a	Ph	2i	CICH ₂ , H, H	3i , 86	5i , 82
4a	Ph	2 j	C_3H_7 , CH_3 , H	3j , 94	5j , 92
4a	Ph	2k	–(CH ₂) ₄ –, H	3k , 92	5k , 92
4a	Ph	21	-(CH ₂) ₅ -, H	31 , 56	51 , 53
4b	4-Me-C ₆ H ₄	2f	PhOCH ₂ , H, H		5m , 92
4c	4-MeO-C ₆ H ₄	2d	(CH ₃) ₂ CHOCH ₂ , H, H		5n , 91
4d	$(CH_3)_2CH$	2f	PhOCH ₂ , H, H		50 , 86
	4a 4b 4c	4a Ph 4b 4-Me-C ₆ H ₄ 4c 4-MeO-C ₆ H ₄	4a Ph 2a 4a Ph 2b 4a Ph 2c 4a Ph 2d 4a Ph 2e 4a Ph 2f 4a Ph 2g 4a Ph 2h 4a Ph 2i 4a Ph 2j 4a Ph 2k 4a Ph 2l 4b 4-Me-C ₆ H ₄ 2f 4c 4-MeO-C ₆ H ₄ 2d	4a Ph 2a Me, H 4a Ph 2b Et, H, H 4a Ph 2c Ph, H, H 4a Ph 2d (CH ₃) ₂ CHOCH ₂ , H, H 4a Ph 2e Ph, Ph, H (cis) 4a Ph 2f PhOCH ₂ , H 4a Ph 2g CH ₂ CCH ₃ COOCH ₂ , H, H 4a Ph 2h CH ₂ CHCH ₂ OCH ₂ , H, H 4a Ph 2i CICH ₂ , H, H 4a Ph 2j C ₃ H ₇ , CH ₃ , H 4a Ph 2k -(CH ₂) ₄ -, H 4a Ph 2l -(CH ₂) ₅ -, H 4b 4-Me-C ₆ H ₄ 2f PhOCH ₂ , H, H 4c 4-MeO-C ₆ H ₄ 2d (CH ₃) ₂ CHOCH ₂ , H, H	4a Ph 2a Me, H 3a, 95 4a Ph 2b Et, H, H 3b, 93 4a Ph 2c Ph, H, H 3c, 94c 4a Ph 2d (CH ₃) ₂ CHOCH ₂ , H, H 3d, 94 4a Ph 2e Ph, Ph, H (cis) 3e, 96 4a Ph 2f PhOCH ₂ , H 3f, 94 4a Ph 2g CH ₂ CCH ₃ COOCH ₂ , H, H 3g, 97 4a Ph 2h CH ₂ CHCH ₂ OCH ₂ , H, H 3h, 90 4a Ph 2i CICH ₂ , H, H 3i, 86 4a Ph 2j C ₃ H ₇ , CH ₃ , H 3j, 94 4a Ph 2k -(CH ₂) ₄ -, H 3k, 92 4a Ph 2l -(CH ₂) ₅ -, H 3l, 56 4b 4-Me-C ₆ H ₄ 2f PhOCH ₂ , H, H 4c 4-MeO-C ₆ H ₄ 2d (CH ₃) ₂ CHOCH ₂ , H, H

^a Reaction conditions: 1 (3.0 mmol), 2 (1.0 mmol), Et₃N (10 mol %), MeNO₂ (2 cm³), 25 °C for 6 h

Experimental

Epoxides, CS₂, nitromethane, bases, and solvents were obtained from Merck and were used without further purification. *N*-Tosylaziridines were prepared using the literature procedures [19]. M.p.: Electrothermal-9100 apparatus. IR Spectra: Shimadzu IR-460 spectrometer. 1 H and 13 C NMR spectra: Bruker DRX-500 AVANCE instrument; in CDCl₃ at 500.1 and 125.7 MHz, resp; δ in ppm, *J* in Hz. EI-MS (70 eV): Finnigan-MAT-8430 mass spectrometer. Elemental analyses (C, H, N) were performed with a Heraeus CHN-O-Rapid analyzer. The results agreed favorably with the calculated values.

General procedure for the preparation of 3, 5, 7, and 8

To a stirred solution of heterocumulene (1–3 mmol) and strained heterocycle (1 mmol), 0.01 g Et_3N (10 mol %) in 3 cm³ MeNO₂ was added. The mixture was stirred for

6–10 h at 25 °C. After completion of the reaction (monitored by TLC), 5 cm³ of cold diethyl ether was added to the reaction mixture. Separation of etheric layer and removing of solvent under vacuo gave the pure title products. All the known compounds gave satisfactory spectroscopic values and are analog to spectroscopic data reported in literature [14, 16, 18].

5-Methyl-5-propyl-1,3-oxathiolane-2-thione (3j, $C_7H_{12}OS_2$)

The crude product was purified by cold etheric extraction affording 0.16 g (94 %) **3j**. Yellow oil; IR (KBr): $\bar{v} = 3038$, 2981, 1626, 1541, 1347, 1336, 1108 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): $\delta = 0.95$ (t, ³J = 6.4 Hz, Me), 1.21 (s, Me), 1.29–1.38 (m, 2 CH₂), 3.35 (d, ²J = 11.4 Hz, CH), 3.49 (d, ²J = 11.4 Hz, CH) ppm; ¹³C NMR (125.7 MHz, CDCl₃): $\delta = 13.5$ (CH₂), 14.2 (Me), 23.5 (Me), 41.1 (CH₂), 52.9 (CH₂), 84.3 (C), 228.2 (C) ppm; EI-MS (70 eV): m/z (%) = 176 (M⁺, 5), 160 (22), 116 (45), 100 (63), 85 (100), 76 (78).



^b Reaction conditions: **4** (1.0 mmol), **2** (1.0 mmol), Et₃N (10 mol %), MeNO₂ (2 cm³), 25 °C for 6 h

Table 3 Synthesis of functionalized 1,3-thiazolidines


CS₂
1
or + R⁴

$$R^{1}NCS$$
R²
 R^{3}
 R^{3}
 R^{3}
 R^{3}
 R^{3}
 R^{3}
 R^{4}
 R^{5}
 R^{2}
 R^{3}
 R^{3}
 R^{3}
 R^{3}
 R^{4}
 R^{5}
 R^{5}
 R^{5}
 R^{7}
 $R^$

Entry	4	\mathbb{R}^1	6	R^2 , R^3 , R^4	7 ^a yield/%	8 ^b yield/%
1	4a	Ph	6a	Ph, Ph, H	7a , 89	8a , 85
2	4 a	Ph	6b	H, Ph, H	7b , 90	8b , 88
3	4 a	Ph	6c	Bn, H, H	7c , 93 ^c	8c , 89
4	4a	Ph	6d	C ₄ H ₉ , H, H	7d , 95	8d , 86
5	4a	Ph	6e	C_5H_{11} , CH_3 , H	7e , 82	8e , 81
6	4 a	Ph	6f	Н, Н, Н	7f , 96	8f , 94
7	4a	Ph	6g	TMSCH ₂ CH ₂ , H, H	7g , 95	8g , 89
8	4a	Ph	6h	BnOCH ₂ , H, H	7h , 90	8h , 87
9	4a	Ph	6i	-(CH ₂) ₄ -, H	7i , 86	8i , 82
10	4a	Ph	6 j	–(CH ₂) ₅ –, H	7j , 51	8j , 47
11	4b	4-Me-C ₆ H ₄	6k	Bn, H, H		8k , 89
12	4d	$(CH_3)_2CH$	61	Bn, H, H		81 , 75

^a Reaction conditions: 1 (3 mmol), 6 (1.0 mmol), Et₃N (10 mol %), MeNO₂ (2 cm³), 25 °C for 10 h

Scheme 1



 $\label{eq:hexahydro-3aH-cyclohepta} \textit{Hexahydro-3aH-cyclohepta[d][1,3]oxathiole-2-thione} \\ \textbf{(3l, $C_8H_{12}OS_2$)}$

The crude product was purified by cold etheric extraction affording 0.10 g (56 %) **3l**. Yellow oil; IR (KBr): $\bar{v} = 3041, 2971, 1631, 1547, 1326, 1309, 1107 cm⁻¹; ^1H NMR (500 MHz, CDCl₃): <math>\delta = 1.35-2.18$ (m, 10H), 2.91–2.94 (m, CH), 4.08–4.11 (m, CH) ppm; 13 C NMR (125.7 MHz, CDCl₃): $\delta = 23.2$ (CH₂), 26.5 (CH), 30.1 (CH₂), 30.8 (CH₂), 32.6 (CH₂), 51.8 (CH), 82.1 (CH), 227.9 (C) ppm; EI-MS (70 eV): m/z (%) = 188 (M⁺, 9), 112 (68), 96 (41), 76 (79) 54 (100).

N-(4,5-Diphenyl-1,3-oxathiolan-2-ylidene)benzenamine (**5e**, $C_{21}H_{17}NOS$)

The crude product was purified by cold etheric extraction affording 0.31 g (94 %) **5e**. Pale yellow solid; m.p.: 112-115 °C; IR (KBr): $\bar{v} = 3025$, 2967, 1610, 1547, 1330, 1323, 1113 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): $\delta = 4.41$ (s, CH), 5.76 (s, CH), 7.11–7.35 (m, 15 CH) ppm; ¹³C NMR (125.7 MHz, CDCl₃): $\delta = 44.9$ (CH), 70.1 (CH), 123.1 (2 CH), 127.3 (CH), 127.6 (CH), 128.1 (2 CH), 128.5 (2 CH), 128.7 (CH), 129.5 (2 CH), 129.8 (2 CH), 131.1 (2 CH), 135.6 (C), 137.5 (C), 148.9 (C), 162.5 (C) ppm;



^b Reaction conditions: 4 (1 mmol), 6 (1.0 mmol), Et₃N (10 mol %), MeNO₂ (2 cm³), 25 °C for 10 h

EI-MS (70 eV): m/z (%) = 331 (M⁺, 2), 196 (53), 177 (37), 119 (62), 77 (100).

N-(5-*Methyl-5-propyl-1,3-oxathiolan-2-ylidene*)*benzen-amine* (**5j**, C₁₃H₁₇NOS)

The crude product was purified by cold etheric extraction affording 0.22 g (92 %) **5j**. Pale yellow oil; IR (KBr): $\bar{v}=3038,\ 2970,\ 1617,\ 1548,\ 1321,\ 1310,\ 1108\ {\rm cm}^{-1};\ ^1{\rm H}$ NMR (500 MHz, CDCl₃): $\delta=0.93$ (t, $^3J=6.1$ Hz, Me), 1.24 (s, Me), 1.27–1.36 (m, 2 CH₂), 3.32 (d, $^2J=11.0$ Hz, CH), 3.45 (d, $^2J=11.0$ Hz, CH), 6.91 (d, $^3J=6.8$ Hz, 2 CH), 7.11 (t, $^3J=6.5$ Hz, CH), 7.28 (t, $^3J=6.4$ Hz, 2 CH) ppm; $^{13}{\rm C}$ NMR (125.7 MHz, CDCl₃): $\delta=13.2$ (CH₂), 14.9 (Me), 24.2 (Me), 39.6 (CH₂), 43.2 (CH₂), 73.9 (C), 121.7 (2 CH), 126.1 (CH), 129.6 (2 CH), 147.3 (C), 164.8 (C) ppm; EI-MS (70 eV): m/z (%) = 235 (M⁺, 6), 119 (58), 117 (36), 85 (63), 77 (100).

N-[5-(Phenoxymethyl)-1,3-oxathiolan-2-ylidene]propan-2-amine (**5p**, $C_{13}H_{17}NO_2S$)

The crude product was purified by cold etheric extraction affording 0.22 g (86 %) **5p**. Pale yellow oil; IR (KBr): $\bar{v} = 3025$, 2970, 1644, 1548, 1340, 1314, 1109 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): $\delta = 1.13$ (d, ³J = 6.7 Hz, 2 Me), 3.11–3.15 (m, CH), 3.26-3.32 (m, CH₂), 4.31–4.35 (m, CH₂), 4.93-4.98 (m, CH), 6.89 (d, ³J = 6.7 Hz, 2 CH), 7.05 (t, ³J = 6.3 Hz, CH), 7.17 (d, ³J = 6.8 Hz, 2 CH) ppm; ¹³C NMR (125.7 MHz, CDCl₃): $\delta = 20.1$ (2 Me), 36.2 (CH₂), 48.9 (CH), 69.3 (CH₂), 81.3 (CH), 114.1 (2 CH), 121.3 (CH), 129.8 (2 CH), 159.8 (C), 167.1 (C) ppm; EI-MS (70 eV): mlz(%) = 251 (M⁺, 7), 134 (45), 118 (52), 77 (100), 58 (69).

4,5-Diphenyl-3-tosylthiazolidine-2-thione (**7a**, C₂₂H₁₉NO₂S₃)

The crude product was purified by cold etheric extraction affording 0.38 g (89 %) **7a**. Pale yellow solid; m.p.: 113–115 °C; IR (KBr): $\bar{v} = 3035$, 2978, 1637, 1548, 1341, 1308, 1111 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): $\delta = 2.35$ (s, Me), 4.42 (s, CH), 5.28 (s, CH), 7.08–7.28 (m, 10 CH), 7.33 (d, $^3J = 6.5$ Hz, 2 CH), 7.85 (d, $^3J = 6.7$ Hz, 2 CH) ppm; ¹³C NMR (125.7 MHz, CDCl₃): $\delta = 23.5$ (Me), 54.3 (CH), 68.7 (CH), 126.1 (CH), 126.8 (CH), 127.4 (2 CH), 127.8 (2 CH), 128.1 (2 CH), 128.4 (2 CH), 129.1 (2 CH), 130.0 (2 CH), 135.2 (C), 140.2 (C), 141.7 (C), 145.7 (C), 201.7 (C) ppm; EI-MS (70 eV): m/z (%) = 425 (M⁺, 5), 270 (26), 170 (69), 155 (52), 91 (42), 77 (100).

4-Methyl-4-pentyl-3-tosylthiazolidine-2-thione (7e, $C_{16}H_{23}NO_2S_3$)

The crude product was purified by cold etheric extraction affording 0.29 g (82 %) **7e**. Pale yellow oil; IR (KBr): $\bar{v} = 3037$, 2967, 1638, 1551, 1344, 1312, 1108 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): $\delta = 1.09$ (t, ³J = 6.9 Hz, Me), 1.28 (s, Me), 1.41–1.63 (m, 3 CH₂), 1.81 (t, ³J = 6.7 Hz, CH₂), 2.31 (s, Me), 3.41 (d, ²J = 11.3 Hz, CH), 3.54 (d,

 2J = 11.3 Hz, CH), 7.33 (t, 3J = 6.9 Hz, 2 CH), 7.82 (d, 3J = 6.5 Hz, 2 CH) ppm; 13 C NMR (125.7 MHz, CDCl₃): δ = 15.1 (Me), 21.3 (Me), 22.4 (CH₂), 24.0 (CH₂), 25.6 (Me), 35.7 (CH₂), 37.4 (CH₂), 56.1 (CH₂), 84.1 (C), 126.9 (2 CH), 131.4 (2 CH), 135.8 (C), 142.1 (C), 202.0 (C) ppm; EI-MS (70 eV): m/z (%) = 357 (M⁺, 10), 202 (21), 170 (69), 155 (57), 113 (100), 77 (43).

3-Tosylthiazolidine-2-thione (**7f**, C₁₀H₁₁NO₂S₃)

The crude product was purified by cold etheric extraction affording 0.26 g (96 %) **7f**. Pale yellow oily solid; IR (KBr): $\bar{v}=3025$, 2961, 1642, 1553, 1344, 1310, 1109 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): $\delta=2.26$ (s, Me), 3.46 (t, ${}^3J=7.1$ Hz, CH₂), 4.60 (t, ${}^3J=7.0$ Hz, CH₂), 7.31 (d, ${}^3J=6.7$ Hz, 2 CH), 7.81 (d, ${}^3J=6.2$ Hz, 2 CH) ppm; ¹³C NMR (125.7 MHz, CDCl₃): $\delta=24.4$ (Me), 36.2 (CH₂), 60.1 (CH₂), 127.0 (2 CH), 130.0 (2 CH), 135.9 (C), 141.0 (C), 201.1 (C) ppm; EI-MS (70 eV): m/z (%) = 273 (M⁺, 1), 197 (36), 170 (100), 155 (69), 118 (41), 91 (58).

4-[2-(Trimethylsilyl)ethyl]-3-tosylthiazolidine-2-thione (7g, $C_{15}H_{23}NO_2S_3Si$)

The crude product was purified by cold etheric extraction affording 0.35 g (95 %) **7g**. Pale yellow solid; m.p.: 98-100 °C; IR (KBr): $\bar{v} = 3051$, 2973, 1644, 1551, 1346, 1312, 1112 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): $\delta = 0.04$ (s, 3 Me), 0.70 (t, ${}^3J = 6.8$ Hz, CH₂), 1.72–1.76 (m, CH₂), 2.35 (s, Me), 3.46–3.49 (m, CH₂), 5.12–5.16 (m, CH), 7.32 (d, ${}^3J = 6.5$ Hz, 2 CH), 7.81 (d, ${}^3J = 6.7$ Hz, 2 CH) ppm; ¹³C NMR (125.7 MHz, CDCl₃): $\delta = 0.3$ (3 Me), 13.4 (CH₂), 24.4 (Me), 27.0 (CH₂), 41.2 (CH₂), 65.1 (CH), 126.1 (2 CH), 130.3 (2 CH), 136.8 (C), 142.6 (C), 198.6 (C) ppm; EI-MS (70 eV): m/z (%) = 373 (M⁺, 5), 218 (22), 170 (100), 155 (67), 91 (43).

4-[(Benzyloxy)methyl]-3-tosylthiazolidine-2-thione (**7h**, $C_{18}H_{19}NO_3S_3$)

The crude product was purified by cold etheric extraction affording 0.35 g (90 %) **7h**. Pale yellow solid; m.p.: 119–121 °C; IR (KBr): $\bar{v}=3051,2972,1647,1551,1342,1308,1106 \text{ cm}^{-1}; ^1\text{H NMR } (500 \text{ MHz, CDCl}_3): <math>\delta=2.31 \text{ (s, Me)}, 3.26–3.38 \text{ (m, CH}_2), 4.48–4.71 \text{ (m, 2 CH}_2), 5.31–5.35 \text{ (m, CH)}, 7.11–7.25 \text{ (m, 5 CH)}, 7.32 \text{ (d, }^3J=7.1 \text{ Hz, 2 CH)}, 7.81 \text{ (d, }^3J=6.7 \text{ Hz, 2 CH)} \text{ ppm; }^{13}\text{C NMR } (125.7 \text{ MHz, CDCl}_3): <math>\delta=24.1 \text{ (Me)}, 36.9 \text{ (CH}_2), 68.3 \text{ (CH)}, 73.7 \text{ (CH}_2), 80.4 \text{ (CH}_2), 126.2 (2 \text{ CH)}, 127.0 \text{ (CH)}, 128.3 (2 \text{ CH)}, 129.9 (2 \text{ CH)}, 131.4 (2 \text{ CH)}, 135.8 \text{ (C)}, 136.3 \text{ (C)}, 142.1 \text{ (C)}, 201.1 \text{ (C)} \text{ ppm; EI-MS } (70 \text{ eV}): m/z \text{ (\%)} = 393 \text{ (M}^+, 2), 238 \text{ (37)}, 170 \text{ (72)}, 155 \text{ (69)}, 91 \text{ (100)}, 77 \text{ (59)}.$

N-(4,5-Diphenyl-3-tosylthiazolidin-2-ylidene)benzenamine ($\mathbf{8a}$, $C_{28}H_{24}N_2O_2S_2$)

The crude product was purified by cold etheric extraction affording 0.41 g (85 %) 8a. Pale yellow solid; m.p.: 134–



136 °C; IR (KBr): $\bar{v} = 3046$, 2981, 1623, 1548, 1338, 1305, 1109 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): $\delta = 2.32$ (s, Me), 4.62 (s, CH), 5.38 (s, CH), 7.08-7.31 (m, 15 CH), 7.35 (d, $^3J = 6.7$ Hz, 2 CH), 7.83 (d, $^3J = 6.9$ Hz, 2 CH) ppm; ¹³C NMR (125.7 MHz, CDCl₃): $\delta = 24.0$ (Me), 45.1 (CH), 69.6 (CH), 121.2 (2 CH), 126.0 (CH), 127.1 (2 CH), 128.0 (2 CH), 128.2 (CH), 128.5 (CH), 128.7 (2 CH), 129.0 (2 CH), 129.5 (2 CH), 130.3 (2 CH), 132.5 (2 CH), 135.2 (C), 140.8 (C), 142.1 (C), 143.1 (C), 149.4 (C), 164.2 (C) ppm; EI-MS (70 eV): m/z (%) = 484 (M⁺, 2), 330 (42), 329 (11), 170 (72), 155 (52), 77 (100).

$\label{eq:N-(4-Benzyl-3-tosylthiazolidin-2-ylidene)} \textit{benzenamine} \\ (\textbf{8c}, \, C_{23}H_{22}N_2O_2S_2)$

The crude product was purified by cold etheric extraction affording 0.38 g (89 %) **8c**. Pale yellow solid; m.p.: 100-102 °C; IR (KBr): $\bar{v} = 3046$, 2978, 1644, 1542, 1346, 1312, 1110 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): $\delta = 2.34$ (s, Me), 2.79–2.85 (m, 2 CH), 3.41–3.47 (m, 2 CH), 5.13–5.16 (m, CH), 7.08–7.29 (m, 10 CH), 7.31 (d, $^3J = 6.8$ Hz, 2 CH), 7.83 (d, $^3J = 6.4$ Hz, 2 CH) ppm; ¹³C NMR (125.7 MHz, CDCl₃): $\delta = 24.3$ (Me), 35.9 (CH₂), 43.7 (CH₂), 67.9 (CH), 121.8 (2 CH), 125.3 (CH), 126.7 (2 CH), 127.1 (CH), 127.6 (2 CH), 128.0 (2 CH), 129.8 (2 CH), 131.4 (2 CH), 135.0 (C), 136.3 (C), 142.3 (C), 149.0 (C), 164.7 (C) ppm; EI-MS (70 eV): m/z (%) = 422 (M⁺, 5), 267 (18), 155 (69), 91 (100), 77 (58).

N-(3-Tosylthiazolidin-2-ylidene)benzenamine ($\mathbf{8f}$, $C_{16}H_{16}N_2O_2S_2$)

The crude product was purified by cold etheric extraction affording 0.31 g (94 %) **8f**. Pale yellow solid; m.p.: 86–88 °C; IR (KBr): $\bar{v} = 3037, 2977, 1652, 1549, 1342, 1311, 1110 cm⁻¹;

¹H NMR (500 MHz, CDCl₃): <math>\delta = 2.24$ (s, Me), 3.49 (t, $^{3}J = 6.7$ Hz, CH₂), 4.72 (t, $^{3}J = 6.5$ Hz, CH₂), 7.10 (d, $^{3}J = 6.9$ Hz, 2 CH), 7.18–7.29 (m, 3 CH), 7.32 (d, $^{3}J = 6.5$ Hz, 2 CH), 7.81 (d, $^{3}J = 6.9$ Hz, 2 CH) ppm; ¹³C NMR (125.7 MHz, CDCl₃): $\delta = 24.1$ (Me), 34.9 (CH₂), 59.8 (CH₂), 121.1 (2 CH), 126.0 (CH), 128.2 (2 CH), 130.2 (2 CH), 131.7 (2 CH), 135.8 (C), 142.2 (C), 149.5 (C), 164.9 (C) ppm; EI-MS (70 eV): m/z (%) = 207 (M⁺, 2), 170 (61), 155 (48), 91 (39), 77 (100).

N-[4-[2-(Trimethylsilyl)ethyl]-3-tosylthiazolidin-2-ylidene]benzenamine ($\mathbf{8g}$, $C_{21}H_{28}N_2O_2S_2Si$)

The crude product was purified by cold etheric extraction affording 0.38 g (89 %) **8g**. Pale yellow solid; m.p.: 116–118 °C; IR (KBr): $\bar{v} = 3048$, 2970, 1648, 1544, 1343, 1311, 1116 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): $\delta = 0.08$ (s, 3 Me), 0.79 (t, ³J = 7.1 Hz, CH₂), 1.70–1.74 (m, CH₂), 2.32 (s, Me), 3.39–3.45 (m, CH₂), 5.08–5.12 (m, CH), 7.13 (d, ³J = 6.9 Hz, CH), 7.18 (t, ³J = 7.0 Hz, 2 CH), 7.25 (d, ³J = 6.4 Hz, 2 CH), 7.34 (d, ³J = 6.8 Hz, 2 CH), 7.83 (d, ³J = 6.5 Hz, 2 CH) ppm; ¹³C NMR (125.7 MHz, CDCl₃):

 $\delta = 0.5$ (3 Me), 10.8 (CH₂), 24.1 (Me), 29.3 (CH₂), 36.6 (CH₂), 62.3 (CH), 120.3 (2 CH), 126.7 (CH), 128.0 (2 CH), 130.6 (2 CH), 131.4 (2 CH), 135.2 (C), 141.4 (C), 149.48 (C), 165.8 (C) ppm; EI-MS (70 eV): m/z (%) = 432 (M⁺, 2), 277 (21), 170 (45), 155 (78), 77 (100).

N-[4-[(Benzyloxy)methyl]-3-tosylthiazolidin-2-ylidene]-benzenamine (**8h**, C₂₄H₂₄N₂O₃S₂)

The crude product was purified by cold etheric extraction affording 0.39 g (87 %) **8h**. Pale yellow solid; m.p.: 132–134 °C; IR (KBr): $\bar{v} = 3052$, 2972, 1652, 1551, 1344, 1310, 1109 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): $\delta = 2.34$ (s, Me), 3.32–3.48 (m, CH₂), 4.51–4.79 (m, 2 CH₂), 5.26–5.29 (m, CH), 7.11–7.29 (m, 10 CH), 7.31 (d, $^3J = 6.7$ Hz, 2 CH), 7.82 (d, $^3J = 6.3$ Hz, 2 CH) ppm; ¹³C NMR (125.7 MHz, CDCl₃): $\delta = 24.2$ (Me), 34.5 (CH₂), 69.9 (CH), 71.2 (CH₂), 81.1 (CH₂), 121.3 (2 CH), 127.1 (CH), 127.5 (2 CH), 128.1 (CH), 129.1 (2 CH), 129.6 (2 CH), 130.1 (2 CH), 131.4 (2 CH), 135.0 (C), 137.4 (C), 143.4 (C), 149.9 (C), 165.7 (C) ppm; EI-MS (70 eV): mlz (%) = 452 (M⁺, 2), 297 (18), 170 (70), 155 (51), 91 (100), 77 (62).

N-(4-Benzyl-3-tosylthiazolidin-2-ylidene)-4-methylbenzenamine (**8k**, $C_{24}H_{24}N_2O_2S_2$)

The crude product was purified by cold etheric extraction affording 0.39 g (89 %) **8k**. Pale yellow solid; m.p.: 101–103 °C; IR (KBr): $\bar{v} = 3046$, 2977, 1652, 1550, 1343, 1310, 1107 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): $\delta = 2.29$ (s, Me), 2.32 (s, Me), 2.73–2.80 (m, 2 CH), 3.35–3.43 (m, 2 CH), 5.15–5.19 (m, CH), 7.10 (d, $^3J = 6.7$ Hz, 2 CH), 7.15–7.28 (m, 7 CH), 7.33 (d, $^3J = 6.5$ Hz, 2 CH), 7.85 (d, $^3J = 6.9$ Hz, 2 CH) ppm; ¹³C NMR (125.7 MHz, CDCl₃): $\delta = 23.2$ (Me), 24.5 (Me), 36.5 (CH₂), 40.3 (CH₂), 68.1 (CH), 123.1 (2 CH), 126.0 (CH), 127.1 (2 CH), 127.5 (2 CH), 128.0 (2 CH), 130.6 (2 CH), 132.1 (2 CH), 135.1 (C), 135.7 (C), 139.2 (C), 141.6 (C), 148.3 (C), 165.2 (C) ppm; EI-MS (70 eV): m/z (%) = 436 (M⁺, 2), 128 (23), 170 (38), 155 (45), 91 (100), 77 (63).

$\label{eq:N-(4-Benzyl-3-tosylthiazolidin-2-ylidene)} N-(4-Benzyl-3-tosylthiazolidin-2-ylidene) propan-2-amine \\ \textbf{(8l, $C_{20}H_{24}N_2O_2S_2$)}$

The crude product was purified by cold etheric extraction affording 0.29 g (75 %) **8l**. Pale yellow solid; m.p.: 67–69 °C; IR (KBr): $\bar{v}=3046$, 2977, 1652, 1544, 1349, 1311, 1108 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): $\delta=1.15$ (d, ${}^3J=7.0$ Hz, 2 Me), 2.32 (s, Me), 2.78–2.89 (m, 2 CH), 3.20–3.41 (m, 3 CH), 5.11–5.14 (m, CH), 7.07 (d, ${}^3J=6.4$ Hz, 2 CH), 7.19 (t, ${}^3J=7.1$ Hz, CH), 7.25 (d, ${}^3J=6.7$ Hz, 2 CH), 7.31 (d, ${}^3J=6.5$ Hz, 2 CH), 7.82 (d, ${}^3J=6.7$ Hz, 2 CH) ppm; 13 C NMR (125.7 MHz, CDCl₃): $\delta=21.1$ (2 Me), 24.2 (Me), 37.1 (CH₂), 41.5 (CH₂), 49.2 (CH), 67.3 (CH), 125.2 (CH), 126.7 (2 CH), 127.3 (2 CH), 128.1 (2 CH), 130.3 (2 CH), 135.8 (C), 137.5 (C), 142.1



(C), 164.7 (C) ppm; EI-MS (70 eV): m/z (%) = 388 (M⁺, 1), 233 (31), 170 (58), 155 (46), 91 (100), 77 (62).

Acknowledgments This work was supported by the Young researchers and elite club of IRAN (research grant). We thank Islamic Azad University for additional unrestricted support.

References

- Yudin AK (ed) (2006) Aziridines and Epoxides in Organic Synthesis. Wiley-VCH, Weinheim
- 2. Hu XE (2004) Tetrahedron 60:2701
- 3. ShenYM, Duan WL, Shi M (2003) J Org Chem 68:1559
- Nozaki K, Nakano K, Hiyama T (1999) J Am Chem Soc 121:11008
- 5. Tascedda P, Dunach E (2000) Chem Commun 6:449
- 6. Hancock MT, Pinhas AR (2003) Tetrahedron Lett 44:5457

- Evans DA, Downey CW, Hubbs JL (2003) J Am Chem Soc 125:8706
- 8. McCoull W, Davisb FA (2000) Synthesis 10:1347
- 9. Ferraris D, Cox C, Lectka T (1998) J Org Chem 63:4568
- 10. Khumtaveeporn K, Alper H (1995) Acc Chem Res 28:414
- 11. Fan RH, Hou XL, Dai LX (2004) J Org Chem 69:689
- Evans DA, Downey CW, Hubbs JL (2003) J Am Chem Soc 125:8706
- Murugana R, Anbazhaganb S, Narayanan S (2009) Eur J Med Chem 44:3272
- Yavari I, Ghazanfarpour-Darjani M, Hossaini Z, Sabbaghan M, Hosseini N (2008) Synlett 6:889
- 15. Yavari I, Ghazanfarpour-Darjani M (2014) J Sulfur Chem 35:477
- 16. Samzadeh-Kermani A (2014) Monatsh Chem 145:611
- 17. Sriharshaa SN, Satishb S, Shashikantha S, Raveeshab KA (2006) Bioorg Med Chem 14:7476
- 18. Wu JY, Luo ZB, Dai LX, Hou XL (2008) J Org Chem 73:9137
- Ando T, Kano D, Minakata S, Ryu N, Komatsu M (1998) Tetrahedron 54:13485

